165 related articles for article (PubMed ID: 10350395)
1. Fungal infection and liposomal amphotericin B (AmBisome) therapy in liver transplantation: a 2 year review.
Fisher NC; Singhal S; Miller SJ; Hastings JG; Mutimer DJ
J Antimicrob Chemother; 1999 Apr; 43(4):597-600. PubMed ID: 10350395
[TBL] [Abstract][Full Text] [Related]
2. Systemic mycoses during prophylactical use of liposomal amphotericin B (Ambisome) after liver transplantation.
Lorf T; Braun F; Rüchel R; Müller A; Sattler B; Ringe B
Mycoses; 1999 Apr; 42(1-2):47-53. PubMed ID: 10394848
[TBL] [Abstract][Full Text] [Related]
3. Successful combined antifungal salvage therapy with liposomal amphothericin B and caspofungin for invasive Aspergillus flavus infection in a child following allogeneic bone marrow transplantation.
Kriván G; Sinkó J; Nagy IZ; Goda V; Reményi P; Bátai A; Lueff S; Kapás B; Réti M; Tremmel A; Masszi T
Acta Biomed; 2006; 77 Suppl 2():17-21. PubMed ID: 16918062
[TBL] [Abstract][Full Text] [Related]
4. Prospective interventional study to evaluate the efficacy and safety of liposomal amphotericin B as prophylaxis of fungal infections in high-risk liver transplant recipients.
Castroagudín JF; Pontón C; Bustamante M; Otero E; Martínez J; Tomé S; Conde R; Segade FR; Delgado M; Brage A; Galbán C; Varo E
Transplant Proc; 2005 Nov; 37(9):3965-7. PubMed ID: 16386598
[TBL] [Abstract][Full Text] [Related]
5. Low-dose amphotericin for prevention of serious fungal infection following liver transplantation.
Shah T; Lai WK; Gow P; Leeming J; Mutimer D
Transpl Infect Dis; 2005; 7(3-4):126-32. PubMed ID: 16390401
[TBL] [Abstract][Full Text] [Related]
6. [Diagnosis and treatment of invasive aspergillosis infection following orthotopic liver transplantation].
Yi SH; Chen GH; Lu MQ; Yang Y; Cai CJ; Xu C; Li H; Wang GS; Yi HM
Zhonghua Wai Ke Za Zhi; 2006 Jul; 44(13):885-8. PubMed ID: 17067477
[TBL] [Abstract][Full Text] [Related]
7. Liposomal amphotericin B (AmBisome) efficacy in confirmed invasive aspergillosis and other filamentous fungal infections in immunocompromised hosts: a pooled analysis.
Cordonnier C; Bresnik M; Ebrahimi R
Mycoses; 2007 May; 50(3):205-9. PubMed ID: 17472618
[TBL] [Abstract][Full Text] [Related]
8. Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B.
Offner F; Krcmery V; Boogaerts M; Doyen C; Engelhard D; Ribaud P; Cordonnier C; de Pauw B; Durrant S; Marie JP; Moreau P; Guiot H; Samonis G; Sylvester R; Herbrecht R;
Antimicrob Agents Chemother; 2004 Dec; 48(12):4808-12. PubMed ID: 15561860
[TBL] [Abstract][Full Text] [Related]
9. Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis.
Coukell AJ; Brogden RN
Drugs; 1998 Apr; 55(4):585-612. PubMed ID: 9561346
[TBL] [Abstract][Full Text] [Related]
10. [Aspergillosis in pulmonary transplantation].
de Pablo A; Ussetti P; Cruz Carreño M; Lázaro T; Ferreiro MJ; López A; Mendaza P; Estada J
Enferm Infecc Microbiol Clin; 2000 May; 18(5):209-14. PubMed ID: 10974763
[TBL] [Abstract][Full Text] [Related]
11. Treatment of invasive fungal sinusitis with liposomal amphotericin B: a report of four cases.
Sungkanuparph S; Sathapatayavongs B; Kunachak S; Luxameechanporn T; Cheewaruangroj W
J Med Assoc Thai; 2001 Apr; 84(4):593-601. PubMed ID: 11460976
[TBL] [Abstract][Full Text] [Related]
12. Cerebral aspergillosis in a liver transplant recipient: a case report of long-term survival after combined treatment with liposomal amphotericin B and surgery.
Iemmolo RM; Rossanese A; Rotilio A; Mattisi G; Gerunda GE; Merenda R; Neri D; Crepaldi G; Strazzabosco M
J Hepatol; 1998 Mar; 28(3):518-22. PubMed ID: 9551693
[TBL] [Abstract][Full Text] [Related]
13. Liposomal amphotericin B (AmBisome) reduces dissemination of infection as compared with amphotericin B deoxycholate (Fungizone) in a rate model of pulmonary aspergillosis.
Leenders AC; de Marie S; ten Kate MT; Bakker-Woudenberg IA; Verbrugh HA
J Antimicrob Chemother; 1996 Aug; 38(2):215-25. PubMed ID: 8877535
[TBL] [Abstract][Full Text] [Related]
14. Invasive aspergillosis in liver transplant recipients: outcome comparison of therapy with amphotericin B lipid complex and a historical cohort treated with conventional amphotericin B.
Linden PK; Coley K; Fontes P; Fung JJ; Kusne S
Clin Infect Dis; 2003 Jul; 37(1):17-25. PubMed ID: 12830404
[TBL] [Abstract][Full Text] [Related]
15. Superiority of voriconazole over amphotericin B in the treatment of invasive aspergillosis after heart transplantation.
Wieland T; Liebold A; Jagiello M; Retzl G; Birnbaum DE
J Heart Lung Transplant; 2005 Jan; 24(1):102-4. PubMed ID: 15653389
[TBL] [Abstract][Full Text] [Related]
16. Case reports. Secondary prophylaxis with liposomal amphotericin B after invasive aspergillosis following treatment for haematological malignancy.
Mele L; Pagano L; Equitani F; Leone G
Mycoses; 2001; 44(5):201-3. PubMed ID: 11486459
[TBL] [Abstract][Full Text] [Related]
17. Liposomal amphotericin B as early empiric antimycotic therapy of pneumonia in granulocytopenic patients.
Böhme A; Hoelzer D
Mycoses; 1996; 39(11-12):419-26. PubMed ID: 9144997
[TBL] [Abstract][Full Text] [Related]
18. Resistance to amphotericin B does not emerge during treatment for invasive aspergillosis.
Moosa MY; Alangaden GJ; Manavathu E; Chandrasekar PH
J Antimicrob Chemother; 2002 Jan; 49(1):209-13. PubMed ID: 11751792
[TBL] [Abstract][Full Text] [Related]
19. Liposomal amphotericin B (AmBisome) treatment of invasive fungal infections in immunocompromised children.
Ringdén O; Tollemar J
Mycoses; 1993; 36(5-6):187-92. PubMed ID: 8264715
[TBL] [Abstract][Full Text] [Related]
20. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study.
Kelsey SM; Goldman JM; McCann S; Newland AC; Scarffe JH; Oppenheim BA; Mufti GJ
Bone Marrow Transplant; 1999 Jan; 23(2):163-8. PubMed ID: 10197802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
